CYDY forums/conversation boards are focusing on the wrong issue (2nd Interim analysis of 293 in December). The immediate issue Nader is focusing on is approvals now, based on today's known data and trials and eIND etc., approvals from "other nations". Their criteria for approvals are generally easier to meet. Tuesday Nader said: ".....we are actively talking to other nations about pathways to approval to treat covid-19 patients with leronlimab". And, in Tuesda CC, said they've hired a company to specifically pursue/obtain approval from the Philippines, probalby becasue he knows they may be the quickest and easiest.